Learn About Non-Langerhans-Cell Histiocytosis

What is the definition of Non-Langerhans-Cell Histiocytosis?
Non-Langerhans cell histiocytosis is a group of disorders in which too many white blood cells (histiocytes) that are not Langerhans cells build up in tissues or organs. Types of non-Langerhans cell histiocytosis include hemophagocytic lymphohistiocytosis, sinus histiocytosis, xanthogranuloma, reticulohistiocytoma, and dermatofibroma, among others.
Save information for later
Sign Up
What are the symptoms of Non-Langerhans-Cell Histiocytosis?
Symptoms of non-Langerhans cell histiocytosis include the growth of reddish-brown or reddish-yellow bumps in the skin that may affect internal organs, such as the lungs, liver, or kidneys.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Non-Langerhans-Cell Histiocytosis?
Treatment for non-Langerhans cell histiocytosis is usually not necessary unless internal organs are affected, in which case radiotherapy, surgery, or chemotherapy may be required.
Who are the top Non-Langerhans-Cell Histiocytosis Local Doctors?
Elite
Elite
 
 
 
 
Learn about our expert tiers
Learn more
Elite
What are the latest Non-Langerhans-Cell Histiocytosis Clinical Trials?
Arimoclomol Prospective Doubleblind, Randomised, Placebo-controlled Study in Patients Diagnosed With NiemannPick Disease Type C

Summary: A prospective, randomised, double-blind, placebo controlled therapeutic study in patients with confirmed diagnosis of NiemannPick disease type C (NPC). The purpose of this study is to assess the efficacy and safety of arimoclomol (compared to placebo) when it is administered as an add-on therapy to the patient's current prescribed best standard of care; patient's standard of care may, or may not, ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU)

Summary: Hemophagocytic lymphohistiocytosis in adults (HLH) is at 68% mortality whereas 78% of all cases remain undiagnosed though therapies are available which clearly reduce mortality. The investigators aim to systematically investigate this life-threatening hyperinflammatory syndrome in intensive care units (ICU) in order to detect biomarkers that are highly sensitive and highly specific for HLH in ICU ...

What are the Latest Advances for Non-Langerhans-Cell Histiocytosis?
Anterior nucleus of the thalamus deep brain stimulation vs temporal lobe responsive neurostimulation for temporal lobe epilepsy.
A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: One-year results.
Tired of the same old research?
Check Latest Advances
Efficacy of plasma exchange in children with severe hemophagocytic syndrome: a prospective randomized controlled trial.